Rice Hall James & Associates LLC Makes New Investment in Medpace Holdings, Inc. $MEDP

Rice Hall James & Associates LLC bought a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 54,116 shares of the company’s stock, valued at approximately $28,659,000. Medpace makes up approximately 1.4% of Rice Hall James & Associates LLC’s holdings, making the stock its 15th largest holding. Rice Hall James & Associates LLC owned 0.19% of Medpace at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Geneos Wealth Management Inc. increased its holdings in shares of Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after acquiring an additional 37 shares during the last quarter. Elyxium Wealth LLC bought a new stake in Medpace during the fourth quarter worth approximately $30,000. Allied Private Wealth LLC bought a new position in shares of Medpace in the second quarter valued at approximately $31,000. Basecamp Wealth Advisors LLC lifted its stake in shares of Medpace by 187.5% in the first quarter. Basecamp Wealth Advisors LLC now owns 69 shares of the company’s stock worth $33,000 after buying an additional 45 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of Medpace during the 2nd quarter worth $34,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Insider Buying and Selling at Medpace

In other Medpace news, VP Susan E. Burwig sold 7,500 shares of the firm’s stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $600.00, for a total transaction of $4,500,000.00. Following the completion of the transaction, the vice president owned 62,984 shares in the company, valued at $37,790,400. This trade represents a 10.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, General Counsel Stephen P. Ewald sold 16,349 shares of Medpace stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total value of $7,357,050.00. Following the sale, the general counsel directly owned 20,343 shares in the company, valued at $9,154,350. The trade was a 44.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 67,195 shares of company stock worth $37,989,998. Insiders own 20.50% of the company’s stock.

Medpace Trading Up 3.2%

Shares of NASDAQ MEDP opened at $597.12 on Tuesday. The firm has a market capitalization of $16.67 billion, a price-to-earnings ratio of 35.00, a PEG ratio of 2.58 and a beta of 1.15. Medpace Holdings, Inc. has a one year low of $373.00 and a one year high of $677.90. The business has a fifty day simple moving average of $539.02 and a 200 day simple moving average of $491.54.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. The firm had revenue of $707.33 million for the quarter, compared to the consensus estimate of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The business’s revenue was up 17.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, research analysts anticipate that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. Wall Street Zen downgraded shares of Medpace from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. BMO Capital Markets raised their price target on Medpace from $400.00 to $600.00 and gave the company a “market perform” rating in a research report on Friday, July 24th. Royal Bank Of Canada lifted their price objective on Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a research note on Friday, July 24th. Barclays set a $600.00 target price on Medpace in a research note on Thursday, July 23rd. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a $535.00 target price on shares of Medpace in a report on Thursday, July 23rd. Three research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to MarketBeat, Medpace has a consensus rating of “Hold” and an average target price of $584.18.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.